A pooled analysis of outcomes according to cytogenetic abnormalities in patients receiving ixazomib- vs placebo-based therapy for multiple myeloma.
Journal
Blood cancer journal
ISSN: 2044-5385
Titre abrégé: Blood Cancer J
Pays: United States
ID NLM: 101568469
Informations de publication
Date de publication:
12 01 2023
12 01 2023
Historique:
received:
02
09
2022
accepted:
02
12
2022
revised:
02
12
2022
entrez:
11
1
2023
pubmed:
12
1
2023
medline:
14
1
2023
Statut:
epublish
Résumé
Some cytogenetic abnormalities (CAs) are associated with poorer prognosis in multiple myeloma (MM); proteasome inhibitors appear to benefit patients with high-risk CAs. We evaluated 2247 MM patients from the TOURMALINE-MM1/-MM2/-MM3/-MM4 trials to assess the PFS benefit of ixazomib plus lenalidomide-dexamethasone (Rd) vs placebo-Rd (TOURMALINE-MM1/-MM2) or ixazomib vs placebo (TOURMALINE-MM3/-MM4) in specific high-risk CAs. After a pooled median follow-up of 25.6 months, the hazard ratio (HR) for PFS with ixazomib- vs placebo-based therapy for high-risk patients was 0.74 (95% confidence interval [CI]: 0.59-0.93; median PFS [mPFS] 17.8 vs 13.2 months), and 0.70 (95% CI: 0.62-0.80; mPFS 26.3 vs 17.6 months) for complementary standard-risk patients. The HR for expanded high-risk patients was 0.75 (95% CI: 0.64-0.87; mPFS 18.1 vs 14.1 months), and 0.71 (95% CI: 0.59-0.85; mPFS 36.1 vs 21.4 months) for complementary standard-risk patients. The HR for PFS with ixazomib- vs placebo-based therapy was 0.68 in patients with t(4;14) (95% CI: 0.48-0.96; mPFS 22.4 vs 13.2 months), and 0.77 for patients with amp1q21 (95% CI: 0.63-0.93; mPFS 18.8 vs 14.5 months). A PFS benefit was demonstrated with ixazomib- vs placebo-based therapy regardless of cytogenetic status, with greatest benefit observed in patients with t(4;14) and amp1q21.
Identifiants
pubmed: 36631458
doi: 10.1038/s41408-022-00768-5
pii: 10.1038/s41408-022-00768-5
pmc: PMC9834310
doi:
Substances chimiques
tourmaline
0
Lenalidomide
F0P408N6V4
ixazomib
71050168A2
Dexamethasone
7S5I7G3JQL
Boron Compounds
0
Types de publication
Meta-Analysis
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
14Subventions
Organisme : NCI NIH HHS
ID : P50 CA186781
Pays : United States
Informations de copyright
© 2023. The Author(s).
Références
J Clin Oncol. 2015 Oct 20;33(30):3459-66
pubmed: 26282661
Blood. 2022 Sep 21;:
pubmed: 36130300
Leukemia. 2018 Feb;32(2):383-390
pubmed: 28761118
Ann Hematol. 2020 Jun;99(6):1273-1281
pubmed: 32193630
N Engl J Med. 2016 Apr 28;374(17):1621-34
pubmed: 27119237
Cancers (Basel). 2020 Jan 22;12(2):
pubmed: 31979059
Ann Hematol. 2017 Mar;96(3):431-439
pubmed: 28074255
Lancet. 2019 Jan 19;393(10168):253-264
pubmed: 30545780
Blood. 2012 Sep 27;120(13):2581-8
pubmed: 22889759
Ann Hematol. 2020 Nov;99(11):2589-2598
pubmed: 32892275
Blood. 2021 Mar 4;137(9):1135-1136
pubmed: 33661290
J Hematol Oncol. 2021 Sep 23;14(1):151
pubmed: 34556161
Blood. 2016 Sep 1;128(9):1174-80
pubmed: 27439911
Blood Cancer J. 2020 Aug 11;10(8):82
pubmed: 32782240
J Clin Oncol. 2021 Aug 1;39(22):2430-2442
pubmed: 34111952
J Clin Oncol. 2020 Dec 1;38(34):4030-4041
pubmed: 33021870
Br J Haematol. 2021 Aug;194(3):635-638
pubmed: 33928635
Blood. 2012 Jan 26;119(4):940-8
pubmed: 22160383
Blood. 2021 Jul 1;137(26):3616-3628
pubmed: 33763699
J Clin Oncol. 2010 Oct 20;28(30):4630-4
pubmed: 20644101
Chronic Dis Transl Med. 2021 Aug 31;7(4):220-226
pubmed: 34786541
Blood Cancer J. 2021 Apr 29;11(4):83
pubmed: 33927196
Am J Hematol. 2015 Apr;90(4):314-9
pubmed: 25557740
Blood. 2016 Jun 16;127(24):2955-62
pubmed: 27002115
Blood. 2019 Mar 14;133(11):1217-1221
pubmed: 30692124
Blood Adv. 2017 Feb 27;1(7):449-454
pubmed: 29296960
Am J Hematol. 2020 May;95(5):548-567
pubmed: 32212178
Blood. 2021 Mar 4;137(9):1192-1195
pubmed: 33080624
Leukemia. 2012 Apr;26(4):595-608
pubmed: 22193964
Blood. 2017 Dec 14;130(24):2610-2618
pubmed: 29054911
J Natl Compr Canc Netw. 2020 Dec 02;18(12):1685-1717
pubmed: 33285522